Search research articles
Contact Us
Filters
Showing results (71-80 of 77) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 77 results.
Breast Cancer Research : BCR
|
July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
John M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2015
Addressing overtreatment of screen detected DCIS; the LORIS trial
Adele Francis, Jeremy Thomas, Lesley Fallowfield, et al.
Annals of Surgical Oncology
|
November 30, 2017
Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial
Daniel Rea, Adele Francis, Matthew Wallis, et al.
The Lancet. Oncology
|
May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Helena M Earl, Louise Hiller, Janet A Dunn, et al.
Nature
|
December 7, 2021
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, et al.
Oncotarget
|
April 25, 2015
FKBPL: a marker of good prognosis in breast cancer
Laura Nelson, Hayley D McKeen, Andrea Marshall, et al.
The Western Journal of Emergency Medicine
|
August 12, 2025
Letter of Concern from the Association of Academic Chairs of Emergency Medicine Regarding ACGME Proposed Changes
Richard J Hamilton, Lance B Becker, Richard E Wolfe, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 77) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 77 results.
Breast Cancer Research : BCR
|
July 10, 2010
Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
John M S Bartlett, Jeremy Thomas, Douglas T Ross, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2015
Addressing overtreatment of screen detected DCIS; the LORIS trial
Adele Francis, Jeremy Thomas, Lesley Fallowfield, et al.
Annals of Surgical Oncology
|
November 30, 2017
Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial
Daniel Rea, Adele Francis, Matthew Wallis, et al.
The Lancet. Oncology
|
May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Helena M Earl, Louise Hiller, Janet A Dunn, et al.
Nature
|
December 7, 2021
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, et al.
Oncotarget
|
April 25, 2015
FKBPL: a marker of good prognosis in breast cancer
Laura Nelson, Hayley D McKeen, Andrea Marshall, et al.
The Western Journal of Emergency Medicine
|
August 12, 2025
Letter of Concern from the Association of Academic Chairs of Emergency Medicine Regarding ACGME Proposed Changes
Richard J Hamilton, Lance B Becker, Richard E Wolfe, et al.
Page
of 8